Factors in the Pathogenesis of Dupuytren's Contracture

Journal of Hand Surgery

Volumn 31, Issue 9, 2006, Pages 1527-1534

  Al Qattan, Mohammad M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Dupuytren's contracture; etiology; pathogenesis

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE 3; FIBRONECTIN; FREE RADICAL; GROWTH FACTOR; INTERLEUKIN 1; LYSOPHOSPHATIDIC ACID; NITRIC OXIDE; NUCLEAR FACTOR; PHENOBARBITAL; THYMOSIN; WNT PROTEIN;

AGING; ALCOHOL CONSUMPTION; APOPTOSIS; DIABETES MELLITUS; DRUG EFFECT; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; FIBROBLAST; GENE THERAPY; GENETIC PREDISPOSITION; HUMAN; INJURY; ISCHEMIA; LANGERHANS CELL; MEDICAL RESEARCH; MUSCLE CONTRACTURE; MYOFIBROBLAST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SMOKING; T LYMPHOCYTE; THROMBOCYTE;

ALGORITHMS; DUPUYTREN'S CONTRACTURE; HUMANS;

EID: 33750608334     PISSN: 03635023     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhsa.2006.08.012     Document Type: Review

References (49)

1. Fritzgerald A.M.P., Kirkpatrick J.J.R., and Naylor I.L. Dupuytren's disease. The way forward?. J Hand Surg 24B (1999) 395-399
2. Al-Qattan M.M. Dupuytren's disease in Saudi Arabia. Can J Plast Surg 8 (2000) 185-186
3. Elliot D. The early history of contracture of the palmar fascia. J Hand Surg 13B (1988) 246-253
4. Burge P. Genetics of Dupuytren's disease. Hand Clin 15 (1999) 63-71
5. Murrel G.A.C., Francis M.J.O., and Bromley L. The collagen changes of Dupuytren's contracture. J Hand Surg 16B (1991) 263-266
6. Bayat B., Al Ansar A., Hajeer A.H., Shah M., Watson J.S., Stanley J.K., et al. Genetic susceptibility in Dupuytren's disease. Lack of association of a novel TGF B2 polymorphism in Dupuytren's disease. J Hand Surg 27B (2002) 47-49
7. Pagnotta A., Specchia N., Soccetti A., Manzotti S., and Greco. Responsiveness of Dupuytren's disease fibroblasts to 5 alpha dihydrotestosterone. J Hand Surg 28A (2003) 1029-1034
8. Bayat A., Walter J., Lambe H., Watson J.S., Stanley J.K., Marino M., et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg 115 (2005) 134-141
9. Elliot D., and Ragoowansi R. Dupuytren's disease secondary to acute injury, infection or operation distal to the elbow in the ipsilateral upper limb-a historical review. J Hand Surg 30B (2005) 148-156
10. Larson R.D., Takagishi N., and Posch J.L. The pathogenesis of Dupuytren's contracture. J Bone Joint Surg 42A (1960) 993-1007
11. Plewes L.W. Sudeck's atrophy in hand. J Bone Joint Surg 38B (1956) 195-203
12. Murrel G.A.C., Francis M.J.O., and Howlett C.R. Dupuytren's contracture. Fine structure in relation to aetiology. J Bone Joint Surg 71B (1989) 367-373
13. Rayan G.M., Parizi M., and Tomasek J.J. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. J Hand Surg 21A (1996) 1065-1070
14. Geoghegan J.M., Forbes J., Clark D.I., Smith C., and Hubbard R. Dupuytren's disease risk factors. J Hand Surg 29B (2004) 423-426
15. Al-Qattan M.M. Ischaemia-reperfusion injury. Implications for the hand surgeon. J Hand Surg 23B (1998) 570-573
16. Baird K.S., Crossan J.F., and Ralston S.H. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 46 (1993) 425-428
17. Qureshi F.I., Hornigold R., Spencer J.D., and Hall S.M. Langerhans cells in Dupuytren's contracture. J Hand Surg 26B (2001) 362-367
18. Fritzgerald A.M.P., Kirkpatrick J.J.R., Foo I.T.H., and Naylor I.L. A picropolychrome staining technique applied to Dupuytren's tissue. J Hand Surg 20B (1995) 519-524
19. Gudmundsson K.G., Arngrimsson R., Arinbjarnarson S., Olafsson A., and Jonsson T. T and B lymphocyte subsets in patients with Dupuytren's disease. Correlations with disease severity. J Hand Surg 23B (1998) 724-727
20. Baird K.S., Alwan W.H., Crossan J.F., and Wojciak B. T-cell mediated response in Dupuytren's disease. Lancet 341 (1993) 1622-1623
21. Sugden P., Andrew J.G., Andrew S.M., and Freemont A.J. Dermal dendrocytes in Dupuytren's disease: a link between the skin and pathogenesis?. J Hand Surg 18B (1993) 662-666
22. Andrew J.O., Andrew S.M., Ash A., and Turner B. An investigation into the role of inflammatory cells in Dupuytren's disease. J Hand Surg 16B (1991) 267-271
23. Badalamente M.A., and Hurst L.C. The biochemistry of Dupuytren's disease. Hand Clin 15 (1999) 35-42
24. Badalamente M.A., Sampson S.P., and Hurst L.C. The role of transforming growth factor B in Dupuytren's disease. J Hand Surg 21A (1996) 210-215
25. Bisson M.A., Mc Grouther D.A., Mudera V., and Grobbelaar A.O. The different characteristics of Dupuytren's disease fibroblast derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-B1. J Hand Surg 28B (2003) 351-356
26. Tomasek J.J., Vaughan M.B., and Haaksma C.J. Cellular structure and biology in Dupuytren's disease. Hand Clin 15 (1999) 21-34
27. Brickley-Parsons D., Glimcher M.J., Smith R.J., Albin R., and Adams J.P. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg 63A (1981) 787-797
28. Dolynchuk K.N., and Pettigrew N.M. Transglutaminase levels in Dupuytren's disease. J Hand Surg 16A (1991) 787-790
29. Ulrich D., Hrynschyn K., and Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast Reconstr Surg 112 (2003) 1279-1286
30. Hutchinson J.W., Tierney G.M., Parsons S.L., and Davis T.R.C. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg 80B (1998) 907-910
31. Bailey A.J., Tarltan J.F., Van Der Steppen J., Sims T.J., and Messina A. The continuous elongation technique for severe Dupuytren's disease. A biomechanical mechanism. J Hand Surg 19B (1994) 522-527
32. Tarltan J.F., Meagher P., Brown R.A., Mc Grouther D.A., Bailey A.J., and Afoke A. Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytren's disease tissue. J Hand Surg 23B (1998) 297-302
33. Ketchum L.D., and Danahue T.K. The injection of nodules of Dupuytren's disease with triamcinalone acetonide. J Hand Surg 25A (2000) 1157-1162
34. Badalamante M.A., Hurst L.C., and Hentz V.R. Collagen as a clinical target: non operative treatment of Dupuytren's disease. J Hand Surg 27A (2002) 788-798
35. Al Qattan M.M. The injection of nodules of Dupuytren's disease with triamcinalone acetonide. J Hand Surg 26A (2001) 560-561
36. Pittet B., Rubbia-Braudt L., Desmouliere A., et al. Effect of gamma interferon on the clinical and biological evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg 93 (1994) 1224-1235
37. Meek R.M.D., McLellan S., Reilly J., and Crossan J.F. The effect of steroids on Dupuytren's disease. Role of programmed cell death. J Hand Surg 27B (2002) 270-273
38. Jemec B., Grobbelaar A.O., Wilson G.D., Smith P.J., Sanders R., and Mc Grouther D.A. Is Dupuytren's disease caused by an imbalance between proliferation and cell death. J Hand Surg 24B (1999) 511-514
39. Hsu C., and Chang J. Clinical implications of growth factors in flexor tendon wound healing. J Hand Surg 29A (2004) 551-563
40. Qian A., Meals R.A., Rajfer J., and Conzalez-Cadavid N.F. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64 (2004) 399-404
41. Jacob T., Hingorani A., and Ascher E. Over-expression of transforming growth factor beta 1 correlates with increased synthesis of nitric oxide synthase in varicose veins. J Vasc Surg 41 (2005) 523-530
42. Chester A.H., Borland J.A., Buttery L.D., et al. Induction of nitric oxide synthase in human vascular smooth muscle interactions between pro-inflammatory cytokines. Cardiovasc Res 38 (1998) 814-821
43. Upchurch G.R., Ford J.W., Weiss S.J., Knipp B.S., Peterson D.A., Thompson R.W., et al. Nitric oxide inhibition increases MMP9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg 34 (2001) 76-83
44. Fujita K., Sandford A.P., Kobayashi M., Hanafusa T., Herndon D.N., and Suzuki F. Role of natural killer T (NKT) cells lacking interleukin (IL) 4 producing abilities on the cc-chemokine ligand 2-associated herpes simplex virus type 1 infection in human severe combined immunodeficiency (SCID) mouse chimeras. Burns 31 (2005) 145-152
45. Chen X.L., Xia Z.F., Yu Y.X., Wei D., Wang C.R., and Ben D.F. p38 mitogen activated protein kinase inhibition attenuates burn induced liver injury in rats. Burns 31 (2005) 320-330
46. Bowley E., Mulvihill E., Howard J.C., O'Gorman D., and Gan B.S. GSK-3 beta activity is abnormal in Dupuytren's contracture. Can J Plast Surg 13 (2005) 90
47. Howard J.C., Varallo V.M., Ross D.C., Roth J.H., Faber K.J., Alman B., et al. Elevated levels of beta catenin and fibronectin in 3 dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. Musculoskeletal Disorders 4 (2003) 16-26
48. Liu W., Chua C., Wu X., Wang D., Ying D., Cui L., et al. Inhibiting scar formation in rat wounds by adenovirus-mediated over expression of truncated TGF-beta receptor 2. Plast Reconstr Surg 115 (2005) 860-870
49. Shin S.S., Liu C., Chang E.Y., Carlson C.S., and Di Cesare P.E. Expression of bone morphogenetic proteins by Dupuytren's fibroblast. J Hand Surg 29A (2004) 809-814